Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Shockwave Medical (SWAV) Stock Forecast & Price Target

Shockwave Medical logo
Get the Latest News and Ratings for SWAV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Shockwave Medical and its competitors.

Sign Up

SWAV Analyst Ratings Over Time

TypeCurrent Forecast
11/6/23 to 11/5/24
1 Month Ago
10/7/23 to 10/6/24
3 Months Ago
8/8/23 to 8/7/24
1 Year Ago
11/6/22 to 11/6/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
8 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
10 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$320.50$320.50$309.11$273.56
Forecasted Upside-4.26% Downside-4.26% Downside-7.66% Downside27.29% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

SWAV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SWAV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Shockwave Medical Stock vs. The Competition

TypeShockwave MedicalMedical CompaniesS&P 500
Consensus Rating Score
2.10
2.79
2.50
Consensus RatingHoldModerate BuyHold
Predicted Upside-4.26% Downside16,383.89% Upside10.49% Upside
News Sentiment Rating
Neutral News

See Recent SWAV News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/8/2024Leerink Partners
1 of 5 stars
 Reiterated RatingOutperform ➝ Market Perform$361.00 ➝ $335.00+2.79%
4/8/2024CL King
3 of 5 stars
 Reiterated RatingBuy ➝ Neutral
4/8/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Reiterated RatingBuy ➝ Hold$270.00 ➝ $335.00+2.67%
4/8/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$285.00 ➝ $335.00+2.65%
4/5/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/5/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$263.00 ➝ $335.00+2.51%
4/5/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
4/5/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Peer Perform
4/2/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$290.00 ➝ $360.00+12.32%
2/16/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$200.00 ➝ $210.00-20.74%
9/29/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$218.00+6.11%
5/9/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
4/11/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$235.00 ➝ $275.00+21.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:39 AM ET.


SWAV Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Shockwave Medical is $320.50, with a high forecast of $368.00 and a low forecast of $210.00.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 9 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SWAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWAV, but not buy additional shares or sell existing shares.

According to analysts, Shockwave Medical's stock has a predicted downside of -4.26% based on their 12-month stock forecasts.

Analysts like Shockwave Medical less than other "medical" companies. The consensus rating for Shockwave Medical is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SWAV compares to other companies.


This page (NASDAQ:SWAV) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners